'SGLT2·DPP4' comb market records robust growth
By Kim, Jin-Gu | translator Hong, Ji Yeon
24.11.04 05:58:12
가나다라
0
Esgliteo·Zemidapa·Qtern sales rise…the other 50 companies generated below KRW 500 million

▲Product photos of Qtern, Esgliteo, Esgliteo, and Sugadapa (clockwise from upper left).
The market for combination drugs containing SGLT-2 inhibitor and DPP-4 inhibitor for treating type 2 diabetes is showing rapid growth. The industry expects the market size to expand by over KRW 30 billion this year.
Products containing one or more original active ingredients are leading the market growth. Boehringer Ingelheim's 'Esgliteo' ranked top in prescription sales with cumulative sales of KRW 8.6 billion this year. It was followed by LG Chem's 'Zemidapa,' with KRW 6.1 billion, and AstraZeneca Korea's Qtern, with KRW 3.5 billion.
'SGLT2i+DPP4i combination drugs' generated KRW 9.5B in Q3…Will it surpass yearly KRW 30B?
According to a pharmaceutical mark
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)